In early 2008, Brooks reported the anticancer activity of HNO by demonstrating the ability of HNO to suppress the proliferation of both estrogen receptor- (ER-) positive and ER-negative human breast cancer cell lines, in a dose-dependent manner. The gene discussed is ESR1; the disease is breast cancer.